327 related articles for article (PubMed ID: 29032494)
1. The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus.
Jiang LL; Wang SQ; Ding B; Zhu J; Jing T; Ye L; Lee KO; Wu JD; Ma JH
J Endocrinol Invest; 2018 May; 41(5):539-547. PubMed ID: 29032494
[TBL] [Abstract][Full Text] [Related]
2. Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy.
Traina AN; Lull ME; Hui AC; Zahorian TM; Lyons-Patterson J
Can J Diabetes; 2014 Aug; 38(4):269-72. PubMed ID: 24797495
[TBL] [Abstract][Full Text] [Related]
3. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
[TBL] [Abstract][Full Text] [Related]
4. Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial.
Xu S; Liu X; Ming J; Ji Q
Trials; 2016 Mar; 17():160. PubMed ID: 27009108
[TBL] [Abstract][Full Text] [Related]
5. Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus.
Wu JD; Xu XH; Zhu J; Ding B; Du TX; Gao G; Mao XM; Ye L; Lee KO; Ma JH
Diabetes Technol Ther; 2011 Feb; 13(2):143-8. PubMed ID: 21284481
[TBL] [Abstract][Full Text] [Related]
6. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.
Bunck MC; Diamant M; Cornér A; Eliasson B; Malloy JL; Shaginian RM; Deng W; Kendall DM; Taskinen MR; Smith U; Yki-Järvinen H; Heine RJ
Diabetes Care; 2009 May; 32(5):762-8. PubMed ID: 19196887
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
[TBL] [Abstract][Full Text] [Related]
8. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
Guo XH
Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.
Inagaki N; Atsumi Y; Oura T; Saito H; Imaoka T
Clin Ther; 2012 Sep; 34(9):1892-908.e1. PubMed ID: 22884767
[TBL] [Abstract][Full Text] [Related]
10. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
[TBL] [Abstract][Full Text] [Related]
12. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.
Yoon NM; Cavaghan MK; Brunelle RL; Roach P
Clin Ther; 2009 Jul; 31(7):1511-23. PubMed ID: 19695400
[TBL] [Abstract][Full Text] [Related]
13. Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.
Renukuntla VS; Ramchandani N; Trast J; Cantwell M; Heptulla RA
J Diabetes Sci Technol; 2014 Sep; 8(5):1011-7. PubMed ID: 25030181
[TBL] [Abstract][Full Text] [Related]
14. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects.
Froud T; Faradji RN; Pileggi A; Messinger S; Baidal DA; Ponte GM; Cure PE; Monroy K; Mendez A; Selvaggi G; Ricordi C; Alejandro R
Transplantation; 2008 Jul; 86(1):36-45. PubMed ID: 18622276
[TBL] [Abstract][Full Text] [Related]
15. GLP-1 Agonists in Type 1 Diabetes Mellitus.
Janzen KM; Steuber TD; Nisly SA
Ann Pharmacother; 2016 Aug; 50(8):656-65. PubMed ID: 27252246
[TBL] [Abstract][Full Text] [Related]
16. Status and trends in the use of insulin analogs, insulin delivery systems and their association with glycemic control: comparison of the two consecutive recent cohorts of Japanese children and adolescents with type 1 diabetes mellitus.
Yamamoto Y; Kikuchi T; Urakami T; Goto M; Tsubouchi K; Sasaki G; Mizuno H; Abe Y; Kitsuda K; Amemiya S; Sugihara S
J Pediatr Endocrinol Metab; 2019 Jan; 32(1):1-9. PubMed ID: 30517078
[TBL] [Abstract][Full Text] [Related]
17. The effect of glycemic variability on counterregulatory hormone responses to hypoglycemia in young children and adolescents with type 1 diabetes.
Alghothani N; Dungan KM
Diabetes Technol Ther; 2011 Nov; 13(11):1085-9. PubMed ID: 21770764
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with glycemic variability in children with type 1 diabetes mellitus based on flash glucose monitoring system.
Zhang L; Guo K; Xu Y; Bai J; Ma Y; Fu L; Liu J; Hu K; Li X; Jiang H; Yang L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 47(4):462-468. PubMed ID: 35545341
[TBL] [Abstract][Full Text] [Related]
19. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Mikhail N
Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
[TBL] [Abstract][Full Text] [Related]
20. Adjunctive Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus.
Harris KB; Boland CL
Pharmacotherapy; 2016 Sep; 36(9):1011-20. PubMed ID: 27485823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
